The convenience of screening for prostate cancer is a matter on which there are conflicting opinions among experts, and various studies conducted by prestigious international societies offer disparate versions of their possible benefits.

The need to use this technique to identify early the presence of this neoplasm has been addressed during the National Congress of SEMERGEN, held last week in Oviedo.

Dr. Brenes Bermudez, coordinator of the Working Group of Urology of SEMERGEN, explained that when the disease is detected through screening, almost in half of the cases, the patient is asymptomatic and early diagnosis does not represent a relevant benefit because the evolution of tumor it will be the same.

Although prostate cancer is the most frequent among Spanish men, it ranks third in the number of deaths due to cancer, since it is responsible for only about 10% of the mortality caused by cancer in men.

For and against screening for prostate cancer

Screening is an essential practice to get an early diagnosis of prostate cancer and, according to dr. Brenes, would be indicated in those patients who present risk factors such as, for example, first-degree family history, especially if those affected developed neoplasia at an early age.

However, it is necessary to take into account its drawbacks, such as complications arising from the postoperative period (which can lead to patient death), overdiagnosis and the possibility of unnecessary treatment.

The congress urology classroom also raised the need for primary care professionals to correctly identify the symptoms manifested by various disorders of the lower urinary tract, to distinguish a benign prostatic hyperplasia from other conditions of the prostate, bladder or nearby organs , which may have similar symptoms.

Source: Spanish Society of Primary Care Physicians (SEMERGEN)

PSA To Test or Not To Test - Mayo Clinic (November 2019).